Synergistic Immunity Induction System Against SARS-CoV-2

A novel system combining a replication-defective adenovirus-based vaccine with distinct technologies such as AI, IoT, blockchain, and novel materials to induce robust immunity against SARS-CoV-2, enhancing vaccine efficacy and monitoring capabilities.

The original patent disclosed a method of inducing immunity against SARS-CoV-2 using spike (S) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus. However, the patent's limitations include the lack of integration with other technologies to enhance vaccine efficacy and monitoring. The new inventive concept addresses these limitations by synergistically combining the adenovirus-based vaccine with AI, IoT, blockchain, and novel materials to create a more powerful system.

The new inventive concept comprises a replication-defective adenovirus encoding a CoV2 nucleocapsid protein fused to an endosomal targeting sequence (N-ETSD) and a CoV2 spike protein sequence optimized for cell surface expression. This adenovirus is administered in combination with an artificial intelligence-powered diagnostic tool for detecting SARS-CoV-2 infection, a blockchain-based tracking system for monitoring vaccine distribution and administration, and an IoT-enabled sensor for detecting SARS-CoV-2 antigens in a patient's bodily fluids. The system can also be formulated with novel materials having enhanced immunogenic properties. The adenovirus-based vaccine induces robust immunity against SARS-CoV-2, while the integrated technologies enhance vaccine efficacy, monitoring, and distribution.

The new claims introduce the concept of synergistically combining the adenovirus-based vaccine with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for inducing immunity against SARS-CoV-2.

Alternative embodiments of the inventive concept could include using different AI-powered diagnostic tools, blockchain-based tracking systems, or IoT-enabled sensors. Variations could also include formulating the vaccine composition with different novel materials or using distinct adenovirus-based vaccine constructs.

The synergistic immunity induction system against SARS-CoV-2 has significant commercial potential in the vaccine industry, particularly in the context of pandemic preparedness and response. The system's ability to enhance vaccine efficacy, monitoring, and distribution could lead to widespread adoption in healthcare systems globally.